Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rituximab on Humoral Immune Responses in B-cell Non-Hodgkin's Lymphoma
2004-004774-85Phase 4Completed
- Sponsor
- Biogen
- Start
- Feb 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Biogen. Primary endpoint: Immunological recall response to tetanus vaccine. Started Feb 2005; status: completed.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2004-004774-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004774-85.